News

Doping for UK's biomedicine
Enlarge image

BusinessUK

Doping for UK's biomedicine

03.08.2012 - The UK government has pledged to invest additional €49m (£39m) in the country's life science research.

The Biomedical Catalyst Fund commited €12,6m (£10m) to 14 universities and 18 small- and medium-sized enterprises (SMEs) to explore the market potential of early-stage ideas. Each of the universities received up to £750k, while each company received up to £150k to propel their projects. These are the first investments for the three-year, €227m (£180m) fund. It is part of the Strategy for Life Science unveiled by UK’s Prime Minister David Cameron December last year to foster the domestic life science industry. The grants will fund about 150 pilot projects, allowing academic researchers to begin the process of turning a bright idea into a viable proposition. Universities have control over allocating the funding internally, allowing them to respond rapidly to new opportunities and have the flexibility to pursue the most promising translational research opportunities.

In an effort to establish four e-health centres of excellence in London, Manchester, Dundee and Swansea, UK’s Medical Research Council has teamed up with a consortium of ten public and charity research funders. The centres will focus on conditions including cancer, diabetes, obesity and cardiovascular disease. The researchers working at these centers will link information in NHS health records with other forms of research and routinely-collected data to improve patient care and public health.

Only days ago, Cameron unveiled plans to converse the Olympic drug testing laboratories located in Harlow into a phenome research centre after the Games are complete. The concept of the phenome encapsulates all of an individual’s traits, which are the outcome of a continuous interplay between their genes and the environment. It will be funded by €12,6m (£10m) investments over five years by both the Medical Research Council and the Department of Health’s National Institute for Health Research. Two companies who make scientific instruments - Bruker, and Waters Corporation – will invest additional €25,2m (£20m). Imperial College and King’s College London will be academic partners in the project.

http://www.european-biotechnology-news.com/news/news/2012-03/doping-for-uks-biomedicine.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2085.7%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR146.7%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.8%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 20.10.2014